WO2009114560A3 - Compositions and methods for the therapy and diagnosis of cytomegalovirus infections - Google Patents

Compositions and methods for the therapy and diagnosis of cytomegalovirus infections Download PDF

Info

Publication number
WO2009114560A3
WO2009114560A3 PCT/US2009/036706 US2009036706W WO2009114560A3 WO 2009114560 A3 WO2009114560 A3 WO 2009114560A3 US 2009036706 W US2009036706 W US 2009036706W WO 2009114560 A3 WO2009114560 A3 WO 2009114560A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
methods
compositions
therapy
cytomegalovirus infections
Prior art date
Application number
PCT/US2009/036706
Other languages
French (fr)
Other versions
WO2009114560A2 (en
Inventor
Ole Olsen
Original Assignee
Spaltudaq Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP09720032.3A priority Critical patent/EP2257571B1/en
Priority to CA2718878A priority patent/CA2718878A1/en
Priority to CN200980116708.0A priority patent/CN102015766B/en
Priority to MX2010009885A priority patent/MX2010009885A/en
Priority to AU2009223688A priority patent/AU2009223688B2/en
Priority to ES09720032.3T priority patent/ES2542308T3/en
Application filed by Spaltudaq Corporation filed Critical Spaltudaq Corporation
Priority to JP2010550824A priority patent/JP5544309B2/en
Publication of WO2009114560A2 publication Critical patent/WO2009114560A2/en
Publication of WO2009114560A3 publication Critical patent/WO2009114560A3/en
Priority to IL208086A priority patent/IL208086A/en
Priority to HK11105423.3A priority patent/HK1151304A1/en
Priority to IL236601A priority patent/IL236601A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus

Abstract

The present invention provides novel anti-cytomegalovirus antibodies recognizing the neutralizing epitope AD2-S1 of gB and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.
PCT/US2009/036706 2008-03-10 2009-03-10 Compositions and methods for the therapy and diagnosis of cytomegalovirus WO2009114560A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2718878A CA2718878A1 (en) 2008-03-10 2009-03-10 Compositions and methods for the therapy and diagnosis of cytomegalovirus
CN200980116708.0A CN102015766B (en) 2008-03-10 2009-03-10 Compositions and methods for the therapy and diagnosis of cytomegalovirus
MX2010009885A MX2010009885A (en) 2008-03-10 2009-03-10 Compositions and methods for the therapy and diagnosis of cytomegalovirus infections.
AU2009223688A AU2009223688B2 (en) 2008-03-10 2009-03-10 Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
ES09720032.3T ES2542308T3 (en) 2008-03-10 2009-03-10 Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
EP09720032.3A EP2257571B1 (en) 2008-03-10 2009-03-10 Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
JP2010550824A JP5544309B2 (en) 2008-03-10 2009-03-10 Compositions and methods for treatment and diagnosis of cytomegalovirus infection
IL208086A IL208086A (en) 2008-03-10 2010-09-12 Antibody against cytomegalovirus, compositions comprising the same and uses thereof
HK11105423.3A HK1151304A1 (en) 2008-03-10 2011-05-31 Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
IL236601A IL236601A0 (en) 2008-03-10 2015-01-06 Antibody against cytomegalovirus, compositions comprising the same and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6879808P 2008-03-10 2008-03-10
US61/068,798 2008-03-10

Publications (2)

Publication Number Publication Date
WO2009114560A2 WO2009114560A2 (en) 2009-09-17
WO2009114560A3 true WO2009114560A3 (en) 2009-11-12

Family

ID=41019410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/036706 WO2009114560A2 (en) 2008-03-10 2009-03-10 Compositions and methods for the therapy and diagnosis of cytomegalovirus

Country Status (11)

Country Link
US (4) US7982012B2 (en)
EP (1) EP2257571B1 (en)
JP (3) JP5544309B2 (en)
CN (1) CN102015766B (en)
AU (1) AU2009223688B2 (en)
CA (1) CA2718878A1 (en)
ES (1) ES2542308T3 (en)
HK (1) HK1151304A1 (en)
IL (2) IL208086A (en)
MX (1) MX2010009885A (en)
WO (1) WO2009114560A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2718878A1 (en) * 2008-03-10 2009-09-17 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus
EA201270662A1 (en) 2009-12-23 2013-01-30 4-Антибоди Аг BINDING ELEMENTS FOR HUMAN CYTAMEGALOVIRUS
AU2011268277B2 (en) * 2010-06-16 2016-10-27 Trellis Bioscience, Llc High affinity human antibodies to human Cytomegalovirus (CMV) gB protein
WO2014172623A1 (en) * 2013-04-19 2014-10-23 Ole Olsen Compositions and methods for the therapy and diagnosis of cytomegalovirus
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3445393A4 (en) * 2016-04-20 2020-08-05 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN112898414A (en) 2019-12-04 2021-06-04 珠海泰诺麦博生物技术有限公司 Anti-human cytomegalovirus antibodies and uses thereof
TWI810589B (en) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide
CN114907475B (en) * 2022-05-31 2023-06-02 合肥中科长木生物科技有限公司 Nanometer antibody for resisting influenza A virus M2 antigen and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021952A1 (en) * 1992-04-23 1993-11-11 Bioinvent International Ab Human monoclonal antibodies against cytomegalovirus and method for preparation thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) * 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) * 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) * 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) * 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) * 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) * 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) * 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) * 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) * 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) * 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) * 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) * 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) * 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) * 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) * 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) * 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4313946A (en) * 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) * 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) * 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4676202A (en) * 1986-05-05 1987-06-30 Johnson Kenneth A Engine cooling system
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) * 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE69233254T2 (en) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
JP3951062B2 (en) * 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DE122004000036I1 (en) 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutic use of chimeric and labeled antibodies to human B lymphocyte limited differentiation antigen for the treatment of B-cell lymphoma.
US5614870A (en) * 1993-04-20 1997-03-25 Rca Thomson Licensing Corporation Phase lock loop with idle mode of operation during vertical blanking
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) * 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP1241264A1 (en) 1994-12-02 2002-09-18 Chiron Corporation Monoclonal antibodies to colon cancer antigen
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) * 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) * 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
WO2003083061A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
US7704510B2 (en) * 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
CL2007002225A1 (en) * 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
CA2718878A1 (en) * 2008-03-10 2009-09-17 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus
EP2550362B1 (en) * 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
AU2011268277B2 (en) * 2010-06-16 2016-10-27 Trellis Bioscience, Llc High affinity human antibodies to human Cytomegalovirus (CMV) gB protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021952A1 (en) * 1992-04-23 1993-11-11 Bioinvent International Ab Human monoclonal antibodies against cytomegalovirus and method for preparation thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BABCOOK J S ET AL: "A NOVEL STRATEGY FOR GENERATING MONOCLONAL ANTIBODIES FROM SINGLE, ISOLATED LYMPHOCYTES PRODUCING ANTIBODIES OF DEFINED SPECIFICITIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 93, no. 15, 23 July 1996 (1996-07-23), pages 7843 - 7848, XP000608647, ISSN: 0027-8424 *
MCLEAN GARY R ET AL: "Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 174, no. 8, 1 April 2005 (2005-04-01), pages 4768 - 4778, XP002505839, ISSN: 0022-1767 *
OHLIN MATS ET AL: "Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies", JOURNAL OF VIROLOGY, vol. 67, no. 2, 1993, pages 703 - 710, XP002544755, ISSN: 0022-538X *
SCHRADER ET AL: "Location, location, timing: Analysis of cytomegalovirus epitopes for neutralizing antibodies", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 112, no. 1, 15 September 2007 (2007-09-15), pages 58 - 60, XP022218591, ISSN: 0165-2478 *

Also Published As

Publication number Publication date
WO2009114560A2 (en) 2009-09-17
EP2257571B1 (en) 2015-03-04
AU2009223688B2 (en) 2014-12-11
AU2009223688A1 (en) 2009-09-17
IL208086A0 (en) 2010-12-30
US20090324613A1 (en) 2009-12-31
US20120263734A1 (en) 2012-10-18
EP2257571A2 (en) 2010-12-08
JP2013199490A (en) 2013-10-03
IL236601A0 (en) 2015-02-26
JP2016034984A (en) 2016-03-17
US20110305708A1 (en) 2011-12-15
ES2542308T3 (en) 2015-08-04
CN102015766A (en) 2011-04-13
IL208086A (en) 2015-01-29
CA2718878A1 (en) 2009-09-17
HK1151304A1 (en) 2012-01-27
MX2010009885A (en) 2010-11-30
US7982012B2 (en) 2011-07-19
JP2011518123A (en) 2011-06-23
US20150191531A1 (en) 2015-07-09
JP5544309B2 (en) 2014-07-09
US8852594B2 (en) 2014-10-07
CN102015766B (en) 2014-07-16
US8268309B2 (en) 2012-09-18

Similar Documents

Publication Publication Date Title
WO2009114560A3 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
WO2012021786A3 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
WO2010062396A3 (en) Virus like particle compositions and methods of use
WO2008153610A3 (en) Use of il-23 antagonists for treatment of infection
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2011160119A3 (en) Anti-gd2 antibodies
PL2126049T3 (en) Antibodies against human cytomegalovirus (hcmv)
IL213489A0 (en) Compositions and methods for the treatment of the prevention of e. coli infections and for the eradication or reduction of e. coli surfaces
WO2009055711A3 (en) Anti-rsv g protein antibodies
WO2010083347A3 (en) Peptidomimetic macrocycles
WO2009129246A3 (en) Compositions and methods for preparing and using same
EP3411504A4 (en) Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2009073631A3 (en) Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
WO2009117030A3 (en) Improved compositions for the prevention and treatment of smallpox
WO2011035205A3 (en) Antibodies against candida, collections thereof and methods of use
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2013006569A3 (en) Herpes virus vaccine and methods of use
WO2010032011A8 (en) Anti-fungal therapy
WO2015031778A3 (en) Compositions and methods for the treatment or prevention of tuberculosis
WO2015054600A3 (en) Glycan-interacting compounds and methods of use
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
WO2019106578A3 (en) Polyomavirus neutralizing antibodies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980116708.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09720032

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2718878

Country of ref document: CA

Ref document number: MX/A/2010/009885

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010550824

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3400/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009223688

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009720032

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009223688

Country of ref document: AU

Date of ref document: 20090310

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 236601

Country of ref document: IL